Drugs Safety Labeling Updates
Drugs Safety Labeling Updates
| Scientific Name | Trade Name | Updated Section | Safety-Related Labeling Changes | Date |
|---|---|---|---|---|
| Maraviroc | Celsentri | 4.3 Contraindications | Contraindicated in patients with severe renal impairment or ESRD (CrCl less than 30 mL per minute) who are concomitantly taking potent CYP3A inhibitors or inducers. | Mar,2024 |
| Meningitis B Vaccine | Bexsero | 4.8 Undesirable effects | Blood and lymphatic system disorders, Lymphadenopathy | Mar,2024 |
| COVID-19 Vaccine Moderna | Spikevax | 4.4 Special warnings and precautions for use | Altered immunocompetence | Mar,2024 |
| Lercanidipine | Lercadip | 4.4 Special warnings A185:C185and precautions for use | Sick-sinus syndrome, | Mar,2024 |
| Etanercept | Enbrel | 4.8 Undesirable effects | Glomerulon ephritis | Mar,2024 |
| Pantoprazole | Pantozol | "4.3 Contraindications 4.4 Special warnings and precautions for use 4.5 Interaction with other medicinal products and other forms of interaction" | "Co-administer Rilpivirine Gastric malignancy, Sub-acute cutaneous lupus erythematosus HIV protease inhibitors " | Feb,2024 |